Tumor‐shed antigen CA125 blocks complement‐mediated killing via suppression of C1q‐antibody binding
Open Access
- 24 August 2018
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 48 (11) , 1872-1882
Abstract
C1q‐engagement with IgG and IgM type antibodies is the initiating step of classical complement‐mediated immunity. The tumor shed antigen CA125 has been reported to have immunosuppressive effects on host tumor responses as well as commercially approved and experimental monoclonal antibody (mAb)‐based therapeutic agents. To better understand this effect, molecular and cellular studies were carried out testing the ability of CA125 to perturb the classical complement pathway. Here, we show that patient‐derived CA125 inhibits IgG1, IgG3, and IgM‐mediated complement‐dependent cytotoxicity (CDC) by perturbing antibody‐Fc interaction with the C1q complement‐initiating protein only in those mAbs that are directly bound by CA125. This mechanism was found to impact naturally generated IgM antibodies as well as experimental and clinically approved mAbs, such as farletuzumab and rituximab, respectively. These data support a role for CA125 in humoral immune suppression and as a potential mechanism by which tumors may possibly avoid host immune responses.Keywords
Funding Information
- Morphotek Inc
This publication has 33 references indexed in Scilit:
- FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125Cytogenetic and Genome Research, 2017
- Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagementOncotarget, 2017
- A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive RelapseJournal of Clinical Oncology, 2016
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialThe Lancet Oncology, 2015
- Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasionNature Chemical Biology, 2013
- Immunomodulation of monocyte-derived dendritic cells through ligation of tumor-produced mucins to Siglec-9Biochemical and Biophysical Research Communications, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytesMolecular Cancer, 2010
- Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125)Immunology, 2007
- Complement-inhibiting effect of ovarian cancer antigen CA-125Cancer Letters, 2006